CompletedNot Applicable

TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCC

China1,244 participantsStarted 2022-12-28

Plain-language summary

The purpose of this study is to evaluate the safety and efficacy of transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies in patients with advanced-stage hepatocellular carcinoma (HCC).

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Has a diagnosis of HCC confirmed by radiology, histology, or cytology;
✓. Barcelona Clinic Liver Cancer (BCLC) stage C with the presence of extrahepatic spread and/or macrovascular invasion;
✓. Has not received any previous systemic therapy for HCC (including chemotherapy, molecularly targeted therapy, immunotherapy);
✓. Both PD-1/PD-L1 inhibitors and anti-angiogenesis drugs patients received only include marketed drugs but are not limited to HCC approval;
✓. TACE was performed after the first PD-1/PD-L1 inhibitor/anti-angiogenic drug treatment or before treatment;
✓. Received at least 1 cycle of PD-1/PD-L1 inhibitor/anti-angiogenic drug combination therapy after TACE treatment；
✓. Has repeated measurable intrahepatic lesions;

Exclusion criteria

✕. Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixed hepatocellular/cholangiocarcinoma subtypes(confirmed by histology, or pathology) are not eligible;
✕. Unable to meet criteria of combination timeframe described above;

What they're measuring

Overall Survival(OS)

Timeframe: up to approximately 2 years

Trial details

NCT IDNCT05332821

SponsorZhongda Hospital

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-07-30

View on ClinicalTrials.gov More Hepatocellular Carcinoma trials